Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Morphotek
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of malignant pleural mesothelioma (MPM) with the following characteristics: unresectable disease (or otherwise not a candidate for curative surgery); epithelial type or biphasic (mixed) type with low sarcomatous content.
Measurable disease at Screening by computed tomography (CT)(or magnetic resonance imaging \[MRI\]).
KPS of greater than or equal to 70% at Screening.
Life expectancy of at least 3 months
You may not be if
Sarcomatous type of mesothelioma
Prior systemic therapy or radiotherapy for MPM; local radiotherapy for symptom control (ie, non-curative intent) is permitted.
Confirmed presence of CNS tumor involvement.
Evidence of other active malignancy requiring treatment.
Clareo Health | An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
